EliseAI Funding Round Closes at $4B After $3.7B Valuation Talks

From reported talks to a closed round

In mid-August, reports said EliseAI was negotiating a new round at a $3.7 billion valuation. Six weeks later, the deal closed bigger than that. The New York company sells AI that automates the repetitive work of running apartment buildings and medical offices. It raised $350 million at a $4 billion valuation, with Andreessen Horowitz and Bessemer Venture Partners leading and Ontario Teachers' Pension Plan, Sapphire Ventures and Navitas Capital also taking part.2 Both the amount and the price beat the figures in the first reports.14

Business Insider broke the story on August 17. It said EliseAI was discussing roughly $300 million in new financing at a $3.7 billion valuation, with a16z and Bessemer in line to lead. Its sources warned that the terms were not final and could change.11 The Next Web and Tech Funding News both picked up the report and stressed the same caveat: the company and its investors would not comment, so every number described a deal still in progress.15 The terms did move, and in EliseAI's favor.

This is a pattern worth noting in late-stage venture funding. When a hot round leaks early, the leaked terms often end up as the minimum. Here, the gap between the August report and the September close was $50 million in capital and $300 million in valuation.

The valuation path: $1B to $4B in about two years

What stands out is how fast the valuation has climbed. EliseAI became a unicorn with a $75 million Series D led by Sapphire Ventures in August 2024.9 A year later it raised a $250 million Series E. Reuters reported that the round valued the company at more than $2.2 billion, roughly double its price from a year earlier.6 The new round, which funding trackers call the Series F, nearly doubles the valuation again, about 13 months after the Series E.1716

When the talks first surfaced, several outlets worked out that $3.7 billion would mean about a 68% markup in under a year.1315 At $4 billion, the actual step-up is larger, about 1.8 times the Series E price.17

Coverage of earlier rounds disagrees on one detail: who led the Series E. Reuters, SiliconANGLE and Cooley, the law firm that advised EliseAI, all say Andreessen Horowitz led it, with Bessemer joining as a new investor.6108 At least one investor-club summary and one startup database credit Sapphire with the lead.135 The primary reporting and the company's own counsel agree, so a16z is the better-supported answer. That also makes the September round look like a16z and Bessemer doubling down on a bet they made together a year ago.

Total funding figures also vary because of how debt and older rounds are counted. One detailed tally puts EliseAI's equity raised at about $741.9 million across seven rounds, or roughly $772 million including a $30 million credit line from Bridge Bank.17 Before the new round, other databases put the total somewhere between $383 million and about $400 million.51

The revenue behind the price

EliseAI publishes revenue figures, which many AI startups at this price do not. The company said it passed $100 million in annual recurring revenue in early 2025.6 In June 2026 it said ARR had passed $200 million and that revenue had doubled every year for five years in a row.14

On those figures, Tech Funding News puts the $4 billion valuation at no more than about 20 times ARR. It adds that the multiple is probably lower now, since the revenue number is from June.14 One revenue-multiples tracker put the Series E at about 22 times revenue.9 So the multiple has held roughly steady while the valuation has doubled.

That matters. Revenue has kept pace with the price, so this markup looks less like hype than many AI rounds do. One analysis said 20 times ARR is rich but closer to a normal software multiple than to what investors pay for frontier AI labs. It also noted that EliseAI took seven years to reach a billion-dollar valuation, while some newer AI startups get there in months.17

Why investors are paying for the unglamorous part

Business Insider's framing is that this multibillion-dollar AI startup doesn't write code or generate images. It answers your landlord.11 EliseAI's software handles questions from prospective tenants, books apartment tours, logs maintenance requests and helps with lease renewals across text, email, phone and chat.1513 SiliconANGLE describes a system built around a tenant CRM, with tools that rank repair tickets by urgency and route them to the right technician, plus AI-guided tours that run when no leasing agent is available.10

Coverage broadly agrees on why investors keep paying up. Reuters called EliseAI an example of investor appetite for "vertical AI": companies that build deep, industry-specific products instead of general-purpose models.6 Dealroom wrote that AI built for one industry at a time is now getting valuations once reserved for broader platforms.16 Bessemer describes EliseAI as a vertical operations company rather than a chatbot vendor. It points out that the company fine-tunes open-source models and owns its voice pipeline instead of reselling another firm's product.17

EliseAI's reach in housing is unusually deep. The company has said its platform runs across about 10% of the U.S. apartment market.10 At the time of the Series D, 70% of the 50 largest U.S. residential rental operators were customers.17 Some of the biggest landlords, including AvalonBay and Equity Residential, invested in its earliest rounds. That gave the startup access to large property portfolios and references other operators trusted.17

Healthcare is the second growth story

Housing still brings in most of the revenue, but healthcare is where much of the investor excitement now sits. EliseAI started selling to healthcare in 2022, and Reuters reported that the business was growing quickly even though real estate still made up the majority of revenue.6 The company focuses on outpatient specialties such as dermatology, women's health, ophthalmology and orthopedics. It books appointments directly in electronic health record systems, verifies insurance and handles some prior-authorization and billing questions.3

The Next Web made the case most clearly: a front desk that books apartment tours and one that books patient appointments are close cousins in software terms. Moving into healthcare widened EliseAI's market without changing the product much. That fits the company's own pitch. It says housing and healthcare together make up roughly 40% of household spending.7

What the money will fund

According to Fierce Healthcare, EliseAI plans to use the new capital to automate more of its customers' operations, expand its North American engineering, deployment and sales teams, and make San Francisco a second engineering hub next to its New York headquarters.2 Weeks before the round closed, the company launched Apollo, which it calls its first agentic AI teammate. EliseAI says Apollo can do any task on the Elise platform.2 The company has also signed a 10-year lease for 109,000 square feet at 401 Fifth Avenue in Midtown Manhattan, a sign it plans to keep hiring heavily in New York.12

The company says all $350 million is new capital, with no existing shareholders cashing out.14 That is notable at a time when many late-stage rounds include large secondary sales.

The broader read

The round lands in a split market. Several outlets noted that EliseAI added about $1.5 billion in paper value in a year while many AI startups were struggling to raise money at all.15 The same weeks brought other large rounds, including a $350 million raise for chip startup Groq. Money is concentrating in a small number of companies.

Our read: the EliseAI deal is a clear example of where late-stage capital is going in 2026. Investors are favoring companies with disclosed, recurring revenue, deep customer lock-in and a believable path into a second industry, over model builders with uncertain unit economics. The pension-fund money adds to that picture. Ontario Teachers' joined as a new investor, according to Fortune as cited by Tech Funding News, and capital like that is usually looking for durable revenue, not lottery tickets.14 The open questions are whether healthcare can grow into a real second engine and whether doubling revenue every year can last at $200 million-plus in ARR. For now, the market has priced in the answer it expects.